Luisi Andrea F, Pawasauskas Jayne E
Department of Pharmacy Practice, University of Rhode Island, Kingston, Rhode Island, USA.
Pharmacotherapy. 2003 Sep;23(9):1131-40. doi: 10.1592/phco.23.10.1131.32754.
Premenstrual dysphoric disorder (PMDD) is considered a severe form of premenstrual syndrome. Symptoms of PMDD occur during the last week of the luteal phase of the menstrual cycle and usually abate at the onset of menses. About 3-8% of all menstruating women experience PMDD, which can lead to significant functional impairment. Several randomized, controlled trials have assessed the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of PMDD. The SSRIs were found to significantly improve symptoms, particularly psychological or behavioral symptoms, during the luteal phase in women with PMDD. Also, SSRIs were found to improve the quality of life in women with PMDD. Headache, fatigue, insomnia, and anxiety were often reported as adverse effects. A decrease in libido or sexual dysfunction also was reported. In recent studies, intermittent SSRI therapy was found to be effective treatment for PMDD and allows a woman to take the drug for only 14 days each month. Intermittent SSRI therapy should be recommended before continuous daily dosing of SSRIs in the treatment of PMDD.
经前烦躁障碍（PMDD）被认为是经前综合征的一种严重形式。PMDD的症状出现在月经周期黄体期的最后一周，通常在月经开始时减轻。所有月经女性中约有3-8%经历PMDD，这可能导致显著的功能损害。几项随机对照试验评估了选择性5-羟色胺再摄取抑制剂（SSRI）治疗PMDD的疗效。发现SSRI能显著改善PMDD女性黄体期的症状，尤其是心理或行为症状。此外，还发现SSRI能改善PMDD女性的生活质量。头痛、疲劳、失眠和焦虑常被报告为不良反应。也有报告称性欲减退或性功能障碍。在最近的研究中，发现间歇性SSRI治疗对PMDD有效，且允许女性每月仅服用该药物14天。在治疗PMDD时，应在持续每日服用SSRI之前推荐间歇性SSRI治疗。
